FindTrial
Sign In

vepdegestrant

DRUG8 trials

Sponsors

Pfizer

Conditions

Breast CancerBreast NeoplasmsHealthyHealthy Participants

Phase 1

A Study to Learn About the Vepdegestrant (ARV-471, PF-07850327) in People With ER+/HER2- Locally Advanced or Metastatic Breast Cancer (BC)
Active, not recruitingNCT05463952
PfizerBreast Neoplasms
Start: 2022-08-16End: 2025-03-31Updated: 2024-11-13
A Study to Understand the Effect of Itraconazole on the Levels of a Study Medicine Called ARV-471 in Healthy Adults
CompletedNCT05538312
PfizerHealthy
Start: 2023-02-23End: 2023-05-22Updated: 2024-09-23
A Study to Understand the Effects of Carbamazepine on How Vepdegestrant is Processed in Healthy Participants
CompletedNCT06005688
PfizerHealthy Participants
Start: 2023-08-18End: 2023-11-21Updated: 2024-01-16
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
Active, not recruitingNCT06125522
PfizerBreast Cancer
Start: 2024-01-10End: 2026-12-31Updated: 2026-05-06
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Active, not recruitingNCT06206837
PfizerBreast Cancer
Start: 2024-02-19End: 2026-09-07Updated: 2026-02-27
A Study to Learn If the Study Medicine Called Vepdegestrant Changes How the Body Processes the Other Study Medicine Called Midazolam
CompletedNCT06256510
PfizerHealthy Participants
Start: 2024-02-08End: 2024-05-13Updated: 2025-01-21
A Study to Learn If the Study Medicine Esomeprazole Changes How the Body Processes the Other Study Medicine Vepdegestrant
CompletedNCT06275841
PfizerHealthy
Start: 2024-02-23End: 2024-05-24Updated: 2024-06-03
A Study to Learn How the Body Processes the Study Medicine Called Vepdegestrant in People With Loss of Liver Function
RecruitingNCT07231991
PfizerHealthy Participants
Start: 2025-11-18End: 2026-12-23Target: 24Updated: 2026-04-03

Related Papers

Effect of carbamazepine on the pharmacokinetics of vepdegestrant, a PROteolysis TArgeting Chimera estrogen receptor degrader, in healthy adults.
2026-02-17
The Effect of Itraconazole on the Pharmacokinetics of Vepdegestrant, a PROteolysis TArgeting Chimera Estrogen Receptor Degrader, in Healthy Adult Participants.
2026-01-19
Abstract P4-12-03: Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, Plus Abemaciclib in ER-Pos/Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Advanced or Metastatic Breast Cancer: TACTIVE-U Prelim Phase 1b Results
Clinical Cancer Research2025-06-134 citations
Abstract P4-08-13: Evaluating CYP3A4-Mediated Drug Interaction Risks for Vepdegestrant, a PROteolysis TArgeting Chimera (PROTAC) Estrogen Receptor (ER) Degrader, in Combination With Cyclin-Dependent Kinase (CDK)4/6 Inhibitors and Everolimus
Clinical Cancer Research2025-06-132 citations
Safety and pharmacokinetics of vepdegestrant in Japanese patients with ER+ advanced breast cancer: a phase 1 study.
2024-11-204 citations
VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer
Future Oncology2024-07-2965 citations
TACTIVE-K: Phase 1b/2 study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer.
Journal of Clinical Oncology2024-06-01
264TiP TACTIVE-K: Phase Ib/II study of vepdegestrant, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, in combination with PF-07220060, a cyclin-dependent kinase (CDK)4 inhibitor, in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer
ESMO Open2024-05-013 citations